FDA Fast-Tracks Expanded Access for Promising Pancreatic Cancer Drug Daraxonrasib
The FDA approved expanded access in just 2 days for daraxonrasib, a RAS inhibitor targeting the most common pancreatic cancer mutation.
Summary
The FDA has granted expanded access for daraxonrasib, an experimental drug targeting RAS protein mutations found in most pancreatic cancers. Developed by Revolution Medicines, the drug is now available to eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma outside of clinical trials. The FDA processed the request in just two days, signaling urgency around this deadly disease. Daraxonrasib already holds Breakthrough Therapy and Orphan Drug designations, and the company plans to submit a full new drug application. Pancreatic cancer has one of the lowest survival rates of any cancer, making new treatment options critically important for patients with limited alternatives.
Detailed Summary
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, with a five-year survival rate below 15% and few effective treatment options for metastatic disease. Any credible new therapeutic approach in this space carries significant implications for patients and the broader oncology community.
The FDA issued a 'safe to proceed' letter to Revolution Medicines just two days after receiving the expanded access request, allowing physicians to apply on behalf of eligible patients with previously treated metastatic pancreatic cancer. This rapid turnaround reflects the agency's stated commitment to accelerating access to therapies for life-threatening conditions.
Daraxonrasib, also known as RMC-6236, is a RAS inhibitor — a class of drugs designed to block a mutated protein called RAS, which drives tumor growth in the vast majority of pancreatic cancers. RAS mutations have historically been considered 'undruggable,' making this class of inhibitors a significant scientific breakthrough in cancer biology.
The drug has already received Breakthrough Therapy designation and Orphan Drug designation from the FDA, both of which indicate early evidence of meaningful clinical benefit. Revolution Medicines also plans to submit a full new drug application under the FDA Commissioner's National Priority Voucher pilot program, suggesting a formal approval pathway is actively underway.
For health-conscious individuals and those with family histories of pancreatic cancer, this development is worth monitoring closely. While daraxonrasib is not yet approved and remains investigational, the expanded access program means patients who have exhausted standard treatments may now have a pathway to access it. The speed of FDA action and the drug's multiple designations suggest cautious optimism, though full efficacy and safety data from clinical trials will be essential before broader conclusions can be drawn.
Key Findings
- FDA approved expanded access for daraxonrasib in just 2 days, unusually fast for investigational drugs.
- Daraxonrasib targets RAS mutations present in the majority of pancreatic cancer tumors.
- Drug holds both Breakthrough Therapy and Orphan Drug FDA designations, indicating promising early data.
- Revolution Medicines plans to file a full new drug application, moving toward potential formal approval.
- Eligible patients with previously treated metastatic PDAC can now request access through licensed physicians.
Methodology
This is an official FDA press release, representing a primary regulatory source with high institutional credibility. It reports a regulatory action rather than clinical trial results, so no efficacy or safety data is presented. Evidence basis for the drug's promise rests on prior designations and company disclosures, not peer-reviewed publications cited here.
Study Limitations
No clinical trial efficacy or survival data is presented in this release; the drug remains investigational and unapproved. Expanded access does not confirm safety or effectiveness — full trial results are needed. Eligibility criteria for the expanded access program are not detailed and would require direct inquiry to Revolution Medicines.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.